| Popis: |
Jaycob Avaylon,1 Sol Lee,2 Ron P Gallemore2 1California Northstate University, College of Medicine, Elk Grove, CA, USA; 2Retina Macula Institute, Torrance, CA, USACorrespondence: Ron P GallemoreRetina Macula Institute, 4201 Torrance Blvd., Ste 220, Torrance, CA 90503, USATel +1 310 413-7020Email rongallemoremd@gmail.comPurpose: To report a case series of initial responses to intravitreal brolucizumab in patients already undergoing anti-VEGF therapy for wet age-related macular degeneration.Case Series: Six eyes (6 patients) with a history of wet age-related macular degeneration presented with either decline in vision or no improvement while undergoing treatment with anti-VEGF therapy – aflibercept or bevacizumab. Patients were switched to intravitreal brolucizumab. Four weeks post-injection, there was no significant change in visual acuity. Optical coherence tomography scans were taken and improved IRF/SRF, central macular thickness and average pericentral thickness were observed in all 6 patients. No serious adverse reactions were observed, including signs of vasculitis or increase in anterior chamber cell count at the 4-week follow-up for all 6 patients.Conclusion: Intravitreal brolucizumab appears to be a safe and limitedly effective option for patients with recalcitrant CNV from wet AMD.Keywords: macular degeneration, anti-VEGF, brolucizumab, wet AMD, choroidal neovascularization |
